Toll-like receptor ligands energize peptide vaccines through multiple paths.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 17804699.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The potential of vaccines for cancer therapy or prevention has yet to be realized. Recently, we showed that using an immunologic adjuvant composed of a Toll-like receptor (TLR) ligand can increase the production of antitumor CTLs produced by a peptide vaccine in a mouse model of breast cancer. By increasing the cross talk between the innate and adaptive immune systems, TLR ligands can drive expansion and memory of CTLs that can destroy cancer cells.
Medical subject headings
- Adjuvants, Immunologic
- Ligands
- Neoplasms
- Signal Transduction
- Toll-Like Receptors
- Vaccines, Subunit